1. Discuss the signs and symptoms of stress urinary incontinence versus urgency urinary incontinence. How are they similar? How do they differ? The authors focused their study on the treatment of any urinary incontinence rather than just urgency urinary incontinence. 3. The authors identify their main outcome measure as discontinuation of their anticholinergic medication within 36 months. Treatment discontinuation was defined as a period of 90 days without prescription of urinary incontinence therapy; but, with at least one visit to the same doctor after 90 days. Discuss why this may or may not be a good indication of discontinuation.
4. Discuss the mechanism of action of anticholinergics and why expected side effects in this study included gastrointestinal upset, constipation, dry eyes, and headache. How do cholinergic receptors vary at these different sites?
5. Overall the authors report a very low continuation rate of anticholinergic medication in this largely insured population. Review continuation rates for antihypertensives and lipid-lowering medications. Is the discontinuation rate for anticholinergics different than treatments for other chronic diseases? Discuss why discontinuation rates are high and how providers might address this problem.
6. What other first-line therapies are proven effective for the treatment of urgency urinary incontinence? The authors suggest that physiotherapy was underutilized in this population. Describe how you would counsel patients regarding other therapies for urinary incontinence. 
